SEC Form 4 filed by Maricich Yuri

$PEAR
Computer Software: Prepackaged Software
Technology
Get the next $PEAR alert in real time by email
SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Maricich Yuri

(Last) (First) (Middle)
C/O PEAR THERAPEUTICS, INC.
200 STATE STREET, 13TH FLOOR

(Street)
BOSTON MA 02109

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Pear Therapeutics, Inc. [ PEAR ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Medical Officer
3. Date of Earliest Transaction (Month/Day/Year)
02/15/2023
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units (1) 02/15/2023 A 1,333,333 (2) (2) Class A Common Stock 1,333,333 $0 1,333,333 D
Explanation of Responses:
1. Each restricted stock unit represents a contingent right to receive one share of PEAR Class A Common Stock.
2. The restricted stock units shall vest and settle as to 33% on February 15, 2024; 33% on February 15, 2025; and 34% on February 15, 2026.
/s/ Stacie S. Aarestad, Attorney-in-Fact 02/17/2023
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $PEAR alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$PEAR

DatePrice TargetRatingAnalyst
1/26/2022$5.00Neutral
B of A Securities
1/20/2022$11.00Outperform
Credit Suisse
1/3/2022$12.00Buy
BTIG Research
12/29/2021$13.00Buy
Citigroup
12/22/2021$16.00Buy
Chardan Capital
12/16/2021Outperform
Cowen & Co.
More analyst ratings

$PEAR
Press Releases

Fastest customizable press release news feed in the world

See more
  • Pear Therapeutics Files for Chapter 11 and Will Seek to Sell Assets Through Sales Process

    Pear Therapeutics, Inc. (NASDAQ:PEAR) ("the Company"), a company focused on developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced that the Company and its wholly owned subsidiary, Pear Therapeutics (US), Inc. (collectively, the "Debtors") each voluntarily filed for protection under chapter 11 ("Chapter 11") of the U.S. Bankruptcy Code (the "Bankruptcy Code") in the United States Bankruptcy Court for the District of Delaware (the "Bankruptcy Court") and they intend to pursue a sale of the business or assets under section 363 of the Bankruptcy Code. Prior to the filing of the Chapter 11 cases, the Debtors evaluated a wide ra

    $PEAR
    Computer Software: Prepackaged Software
    Technology
  • Sight Sciences Appoints Ali Bauerlein as Chief Financial Officer

    MENLO PARK, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients' lives, today announces the appointment of Alison "Ali" Bauerlein as its Chief Financial Officer and Treasurer, effective April 3, 2023. "I am incredibly excited to have Ali join Sight Sciences as we scale our business and drive towards profitable growth. Ali is an exceptionally talented professional with a proven track record of leading a rapidly growing medtech organization through multiple phases of growth. Her experience and talent will prov

    $GLS
    $PEAR
    $SGHT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Computer Software: Prepackaged Software
    Technology
  • 5AM Ventures Celebrates 20th FDA Product Approval Investing in Breakthrough Science

    SAN FRANCISCO and BOSTON, March 23, 2023 (GLOBE NEWSWIRE) -- 5AM Ventures is pleased that the U.S. Food and Drug Administration (FDA) approved REZZAYO™ (rezafungin for injection) for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options. REZZAYO is the first new treatment option approved for patients with candidemia and invasive candidiasis in over a decade. REZZAYO was developed by Cidara Therapeutics, Inc. (NASDAQ:CDTX), a company seeded and then supported by 5AM Ventures through its Series A and Series B rounds. 5AM's Scott Rocklage served as chair of the board of directors from the company's inception in 2012 through 2019. "Su

    $CDTX
    $ELVN
    $IMPL
    $PEAR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Computer Software: Prepackaged Software

$PEAR
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$PEAR
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$PEAR
SEC Filings

See more

$PEAR
Leadership Updates

Live Leadership Updates

See more
  • Sight Sciences Appoints Ali Bauerlein as Chief Financial Officer

    MENLO PARK, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients' lives, today announces the appointment of Alison "Ali" Bauerlein as its Chief Financial Officer and Treasurer, effective April 3, 2023. "I am incredibly excited to have Ali join Sight Sciences as we scale our business and drive towards profitable growth. Ali is an exceptionally talented professional with a proven track record of leading a rapidly growing medtech organization through multiple phases of growth. Her experience and talent will prov

    $GLS
    $PEAR
    $SGHT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Computer Software: Prepackaged Software
    Technology
  • Jorge Gomez Joins Moderna as Chief Financial Officer

    CAMBRIDGE, MA / ACCESSWIRE / April 11, 2022 / Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines today announced that Jorge Gomez will join Moderna as Chief Financial Officer, effective Monday, May 9, 2022. He will serve on Moderna's Executive Committee and report to Chief Executive Officer, Stéphane Bancel."I am pleased to welcome Jorge to Moderna as our Chief Financial Officer and as a member of the Executive Committee," said Mr. Bancel. "As we grow and scale the company globally, Jorge's experience leading the financial functions of multinational healthcare companies will be an asset to our team. Jorge's passion for sustainabilit

    $CAH
    $MRNA
    $PEAR
    $XRAY
    Other Pharmaceuticals
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Computer Software: Prepackaged Software

$PEAR
Financials

Live finance-specific insights

See more
  • Pear Therapeutics Reports Third Quarter 2022 Results

    Grew revenue 24% quarter-over-quarter to $4.1 million Expanded patient access with new state and commercial payors Expanded real-world evidence with new peer reviewed publication Reduced quarter-over-quarter operating expenses and cut expected 2023 operating expenses Pear Therapeutics, Inc. (NASDAQ:PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today reported results for its third quarter ended September 30, 2022. "Pear is making strong and steady progress toward our mission of making PDTs mainstream medicine," said Corey McCann, M.D., Ph.D., President and Chief Executive Officer of Pear Therapeutics. "

    $PEAR
    Computer Software: Prepackaged Software
    Technology
  • Pear Therapeutics to Issue Third Quarter 2022 Financial Results on Monday, November 14, 2022

    Pear Therapeutics, Inc. (the "Company") (NASDAQ:PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced it will issue its third quarter 2022 financial results after the close of market on Monday, November 14, 2022. Management will hold its investor conference call and webcast at 4:30 p.m. ET on the same day to discuss the Company's financial and business highlights. To access the live conference call or webcast, participants should register online at https://investors.peartherapeutics.com/news-events/events-presentations. To avoid delays, we encourage participants to register fifteen minutes ahead of the

    $PEAR
    Computer Software: Prepackaged Software
    Technology
  • Pear Therapeutics Reports Second Quarter 2022 Results

    20% quarter-over-quarter revenue growth to $3.3 million Recent real-world health economic data for all three of Pear's commercial products show cost-savings1-3 Recent commercial formulary additions for reSET® and reSET-O® Pear Therapeutics, Inc. (NASDAQ:PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today reported results for its second quarter ended June 30, 2022. "Pear continues to make significant progress in introducing PDTs as an innovative class of medicine," said Corey McCann, M.D., Ph.D., President and Chief Executive Officer of Pear Therapeutics. "We believe our evidence generation strategy is de

    $PEAR
    Computer Software: Prepackaged Software
    Technology

$PEAR
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more